Become A Featured Company

InMed Pharma: A Leader in Cannabinoid Biosynthesis

Ryan Allway

September 20th, 2017

Exclusive, News, Top News

The medical cannabis industry is largely focused on only two cannabinoids – tetrahydrocannabinol (THC) and cannabidiol (CBD) – but there are dozens of others (90+) that could have potentially beneficial therapeutic effects. The industry wide problem? These other minor cannabinoids aren’t easily extracted from botanical cannabis sources. Even if they were, they aren’t present in high enough concentrations to make them economically feasible to extract.

In this article, we will look at how InMed Pharmaceuticals Inc. (CSE: IN) (OTCQB: IMLFF) is leveraging biosynthesis to solve this problem and why investors should take note as it adds key ex-Eli Lilly personnel to its efforts.

Biosynthesis Breakthrough

Biosynthesis is a multi-step, enzyme-catalyzed process of converting substrates to more complex products in living organisms. The most popular drug developed as a result of biosynthesis is insulin, which is produced by inserting human DNA into a host cell (such as e. coli) that replicates to produce human insulin. The process enables the drug to be cost-effectively produced at scale rather than extracted from living organisms.

InMed Pharma is leveraging the same biosynthesis concepts to mass produce specific cannabinoids. Rather than extracting actual cannabinoids, the company simply inserts the desired cannabinoid DNA into an E. coli bacteria, which then mass produces it at scale for researchers to use in therapeutics. This represents a much more cost-effective, scalable, and scientifically-exacting way to develop cannabinoid-based therapeutics.

The company recently retained the consulting services of Ben Paterson, P.E., to assist in defining the pathway for the scale-up, purification, and manufacturing strategies for its biosynthesis program. In the past, Mr. Paterson served as a Senior Engineering Advisor for Eli Lilly & Co. (NYSE: LLY) where he spent 24 years in the biosynthesis division using E. coli biosynthesis techniques to develop numerous products.

“This novel approach to the biosynthesis of cannabinoids is a game-changer for drug development,” said Dr. Vikramaditya Yadav, a co-inventor of the biosynthesis technology, in a recent press release. “The importance of producing cannabinoids that are identical to naturally-occurring compounds cannot be overstated. Many drug development efforts with synthetic derivatives have failed.”

Patent Protection in Place

Earlier this month, InMed Pharma announced that it filed a provisional patent application pertaining to its proprietary biosynthesis platform for the manufacture of cannabinoids that are identical to those found in nature. The patent, once converted into an international PCT application, will provide significant commercial protection for its E. coli based expression system to manufacture any of the 90+ cannabinoid compounds that may have medical use.

Management intends to file additional patents to protect various aspects of its biosynthesis program, including E. coli based patents, gene optimization patents, and other proprietary developments and data patents. The company will actively convert these patents into national-stage filings in all major commercial jurisdictions as well. This IP portfolio could become increasingly valuable over time as the medical cannabis industry matures.

The move to patent the biosynthesis process that it has pioneered within the cannabinoid industry helps solidify its leadership position moving forward. As researchers continue to uncover the benefits of cannabinoids, the company is well-positioned to provide one of the only scalable methods to reproduce cannabinoids – as they appear in nature – at scale. The move could also help its own clinical programs be more effective than the competition.

Significant Expertise

InMed Pharma has an experienced leadership team that’s led by President & CEO Eric A. Adams, who has over 25 years of experience as a seasoned biopharmaceutical executive. Mr. Adams is joined by Dr. Sazzad Hossain, who was a senior scientist at the Biotechnology Research Institute of National Research Council Canada, and Dr. Ado Muhammed, who was the Associate Medical Director at GW Pharmaceuticals plc (NASDAQ: GWPH).

In addition to its management team, the company’s board of directors includes Martin Bott, who serves as VP of Corporate Finance and Investment Banking at Eli Lilly & Company. Prior to that assignment, he served as CFO for both the Diabetes Business and the Global Manufacturing and Quality organizations. This is important because these are the divisions responsible for the biosynthesis processes used to produce insulin.

The Bottom Line

InMed Pharmaceuticals Inc. (CSE: IN) (OTCQB: IMLFF) represents a compelling investment opportunity in the medical cannabis space. In addition to its promising biosynthesis platform, the company has also developed a bioinformatics assessment tool to target specific cannabinoids against important disease and maintains a drug development program that includes INM-750 for Epidermolysis bullosa and INM-085 for glaucoma.

Investors interested in the space may want to keep an eye on the stock as it continues to build out its patent portfolio and develop innovative cannabinoid-based therapeutics using its biosynthesis program and bioinformatics tools.

For more information, visit the company’s website or investor presentation.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading